Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Endometrial Neoplasms 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

pembrolizumab 4Specimen Handling 3Magnetic Resonance Spectroscopy 3tislelizumab 2aflibercept 2Surveys and Questionnaires 2Radiotherapy 2Gene Expression Profiling 2Fentanyl 2Docetaxel 2Diet Therapy 2Blood Specimen Collection 2Biopsy 2trastuzumab deruxtecan 1toripalimab 1spartalizumab 1sargramostim 1rucaparib 1pegfilgrastim 1pazopanib 1olaparib 1milademetan 1entinostat 1durvalumab 1ciforadenant 1ceralasertib 1cemiplimab 1avelumab 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × ceralasertib × Sarcoma × Clear all
NCT04065269 2026-02-20

ATARI

Institute of Cancer Research, United Kingdom

Phase 2 Active not recruiting
174 enrolled
GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡